Interferon alfa in the treatment of philadelphia-negative chronic myeloproliferative neoplasms

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages

  Hasselbalch, Hans Carl ^a   Kiladjian, Jean Jacques ^b   Silver, Richard T ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b SAINT LOUIS HOSPITAL   (France)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ACUTE LEUKEMIA; BONE PAIN; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; GENE FREQUENCY; HUMAN; IMMUNOMODULATION; LETTER; LOW DRUG DOSE; MAINTENANCE THERAPY; MYELOFIBROSIS; MYELOID LEUKEMIA; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHLEBOTOMY; POLYCYTHEMIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA; TREATMENT DURATION;

ADULT; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; REMISSION INDUCTION; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 79959307980     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.6238     Document Type: Letter

References (20)

1. Barbui T, Barosi G, Birgegard G, et al: Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761-770, 2011
2. Tefferi A, Vainchenker W: Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29:573-582, 2011
3. Linkesch W, Gisslinger H, Ludwig H, et al: Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses [in German]. Acta Med Austriaca 12:123-127, 1985
4. Gilbert HS: Long term treatment of myeloproliferative disease with interferon-alpha- 2b: Feasibility and efficacy. Cancer 83:1205-1213, 1998
5. Silver RT: Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 107:451-458, 2006
6. Samuelsson J, Hasselbalch H, Bruserud O, et al: A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: Feasibility, clinical and biologic effects, and impact on quality of life. Cancer 106:2397-2405, 2006 (Pubitemid 43787664)
7. Jabbour E, Kantarjian H, Cortes J, et al: PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: Final results of a phase 2 study. Cancer 110:2012-2018, 2007 (Pubitemid 350036861)
8. Quintás- Cardama A, Kantarjian H, Manshouri T, et al: Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27:5418-5424, 2009
9. Kiladjian JJ, Cassinat B, Chevret S, et al: Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112:3065-3072, 2008
10. Kiladjian JJ, Chomienne C, Fenaux P: Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 22:1990-1998, 2008
11. Hasselbalch HC, Larsen TS, Riley CH, et al: Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms: Status and perspectives. Curr Drug Targets 12:392-419, 2011
12. Larsen TS, Møller MB, de Stricker K, et al: Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera: A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 14:331-334, 2009
13. Kiladjian JJ, Rain JD, Bernard JF, et al: Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 32:417-421, 2006
14. Thoennissen NH, Krug UO, Lee DH, et al: Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 115:2882-2890, 2010
15. Beer PA, Delhommeau F, LeCouédic JP, et al: Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115:2891-2900, 2010
16. Lengfelder E, Griesshammer M, Hehlmann R: Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 22:135-142, 1996 (suppl 1) (Pubitemid 26388543)
17. Silver RT, Vandris K: Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early myelofibrosis. Leukemia 23:1366-1369, 2009
18. Ianotto JC, Kiladjian JJ, Demory JL, et al: PEG-IFN-alpha-2a therapy in patients with myelofibrosis: A study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myé loprolifératifs (FIM). Br J Haematol 146:223-225, 2009
19. Hasselbalch HC: Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer - Time to change our therapeutic attitude with early upfront treatment? Leuk Res 33:11-18, 2009
20. Essers MA, Offner S, Blanco-Bose WE, et al: IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458:904-908, 2009